Biotech – ABIVAX
Studies, carried out by Florence Mahuteau-Betzer in collaboration with Pr. Jamal Tazi (IGMM), and investigating the inhibition of alternative splicing by small molecules, led to the creation of the start-up Splicos, in 2008. Changing its name to Abivax in 2014, the company has co-filed with Institut Curie more than 20 patents, which report their research findings on inhibitors of various viruses (e.g. HIV, ChikV or RSV).
Since 2009, the medicinal chemistry process is entrenched within the unit through a collaborative agreement and the hosting of two employees, Romain Najman and Pauline Fornarelli. After promising results obtained in phase IIa trials upon treating VIH-infected patients with ABX464 molecule, clinical studies are now ongoing to evaluate the potential ability of this drug candidate to treat inflammatory diseases. Results are thus expected in the first half of 2021, from a phase IIb clinical trial in ulcerative colitis (232 patients) and from a phase IIa clinical trial in rheumatoid arthritis (60 patients). Following further success in inhibiting SARS-CoV-2 in infected cells, a phase IIb/III clinical trial in COVID-19 is initiated, from which results are expected at the end of 2020.